Magnetic resonance imaging of bone marrow in oncology, Part 2 by Sinchun Hwang & David M. Panicek
REVIEW ARTICLE
Magnetic resonance imaging of bone marrow in oncology,
Part 2
Sinchun Hwang & David M. Panicek
Received: 19 February 2007 /Revised: 5 March 2007 /Accepted: 7 March 2007 / Published online: 11 May 2007
# ISS 2007
Abstract Magnetic resonance imaging plays an integral
role in the detection and characterization of marrow lesions,
planning for biopsy or surgery, and post-treatment follow-
up. To evaluate findings in bone marrow on MR imaging, it
is essential to understand the normal composition and
distribution of bone marrow and the changes in marrow that
occur with age, as well as the basis for the MR signals from
marrow and the factors that affect those signals; these
points have been reviewed and illustrated in part 1 of this
two-part article. Part 2 will emphasize the practical
application of MR imaging to facilitate differentiation of
normal marrow, tumor, and treatment-related marrow
changes in oncology patients, and will review complemen-
tary MR techniques under development.
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Tumor in marrow
Malignant tumors in marrow can arise from the myeloid
elements of marrow (resulting in leukemia, lymphoma,
myeloma), from the mesenchymal elements of marrow
(resulting in primary sarcoma of bone), or from hematog-
enous metastases to marrow. Tumor can also reach the
marrow by direct extension from a location outside the
bone. Tumors occur more commonly in red marrow
because of its richer vascularity than that of yellow marrow.
Lymphoproliferative diseases
In leukemia, the infiltration of bone marrow typically is
diffuse, resulting in a diffuse decrease in marrow signal
intensity on T1-weighted images. However, very early in
the disease, tumor cells may not completely replace fat cells
in marrow and thus the resultant marrow signals can be
normal on T1- and T2-weighted spin echo (SE) images. In
multiple myeloma, the amount of marrow fat can even
increase initially because the tumor cells produce biochem-
ical factors that inhibit hematopoiesis [1]. When more
extensive, lymphoproliferative tumors in marrow are low in
signal intensity on T1-weighted SE images and high in
signal intensity on T2-weighted SE images.
Bone marrow necrosis (BMN) is an unusual entity that
has been reported to occur in close association with
malignancy, particularly acute lymphocytic leukemia.
BMN is characterized by a loss of myeloid tissue and
marrow fat without trabecular destruction, unlike avascular
necrosis [2]. Despite its relative rarity (0.3–0.4% of marrow
biopsies) [3, 4], it is important to recognize the close
association between BMN and malignancy. In a study of
240 patients with BMN, Janssens et al. [2] reported that
91% of patients were found to have malignancy, with acute
lymphocytic leukemia representing 18% of the cases. BMN
may be found at the time of cancer diagnosis or later in its
course. MR imaging findings of BMN are similar to those
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of avascular necrosis (AVN), although BMN tends to be
more diffuse, involving the axial skeleton without vertebral
collapse; AVN, in contrast, involves periarticular locations
and may progress to vertebral fracture [5].
In multiple myeloma, the infiltrative pattern on MRI is
variable, ranging from normal to focal or diffuse (Fig. 1).
Although diffuse disease may mimic the MRI appearance
of extensive red marrow reconversion (Fig. 1b,c), the signal
intensity on fat-suppressed T2-weighted SE images is
generally considerably higher than that of muscle
(Fig. 1d). Due to the lack of associated osteoblastic activity,
nuclear bone scans and radiographs are often normal in
multiple myeloma, making MRI the most sensitive imaging
method for lesion detection. Studies have shown that MRI
findings correlate with treatment response and survival [1,
6, 7]. Independent studies by Moulopoulos et al. [6] and
Vande Berg et al. [7] suggested that patients with stage I
disease who had normal-appearing bone marrow on MRI
had a longer progression-free interval, and patients with
bone marrow involvement evident on MRI had more rapid
progression of the disease. In a study of 80 patients with
stage III multiple myeloma, Lecouvet et al. [8] showed that
a good or partial response to chemotherapy (determined by
a 50–75% decrease in serum or urine myeloma protein) was
more common in patients with normal-appearing marrow
on MRI than in patients with an abnormal-appearing
marrow (89% versus 68%, respectively). A diffusely
abnormal pattern of bone marrow also correlated with more
marked alterations in other clinical parameters of disease
activity such as serum calcium, t32 microglobulin and
hemoglobin levels, indicating more severe disease than
found in patients with a focally abnormal MRI pattern of
bone marrow [8]. Stabler et al. [1] evaluated five types of
infiltration patterns and confirmed the prognostic value
of MRI in staging of, and in planning treatment for,
multiple myeloma. They also reported a correlation
between the pattern of infiltration and the degree of contrast
enhancement: A greater than 40% increase in signal intensity
compared with baseline after contrast administration corre-
lated with diffuse tumor infiltration of marrow.
Fig. 1 Multiple myeloma: mul-
tifocal and diffuse patterns. a
Coronal T1-weighted spin echo
(SE) MR image shows innu-
merable tiny foci of low signal
intensity on a background of
fatty marrow. b Coronal T1-
weighted SE MR image of a
different patient shows diffuse,
symmetric, low signal intensity
in the marrow of proximal and
mid femurs, mimicking the ap-
pearance of red marrow. c Cor-
onal fat-suppressed T2-weighted
MR image of the left hip of the
same patient as in b reveals
diffuse, markedly high signal
throughout the marrow, indicat-
ing the presence of marrow
disease rather than red marrow
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Lymphoma in bone marrow can also be focal or diffuse.
The ability to detect focal lymphoma has substantial
consequences, as the presence or absence of bone marrow
involvement is used to assess patient prognosis and select the
specific type(s) of therapy [9]. In non-Hodgkin lymphoma,
marrow involvement is more frequent than in Hodgkin
disease (25–45% of patients in the former, versus 5–15% in
the latter) [10]. Because marrow involvement in lymphoma
is often multifocal but not diffuse, a blind biopsy of marrow
can be falsely negative due to sampling error (Fig. 2). This
phenomenon was demonstrated in studies of bilateral
biopsies in which positive findings were present only
unilaterally in 10–40% of patients with marrow involve-
ment by lymphoma and other diseases [11, 12]. MR
imaging can be used to more fully assess marrow
involvement in lymphoma, and to specifically identify
appropriate potential biopsy sites. Also, dynamic contrast-
enhanced MRI may be useful to assess treatment response,
as a decrease in degree of contrast enhancement has been
shown to correlate with a good response or remission [13].
Metastases
Bone marrow metastases are more commonly seen in red
marrow but can be present anywhere that marrow exists.
The MRI appearances of metastases vary depending on the
balance between the tumor and the response of the host bone;
metastases can be osteolytic, osteoblastic or mixed. When
osteolytic, metastases are usually well circumscribed with
low signal intensity on T1-weighted images and moderately
high signal intensity on T2-weighted images. In osteoblastic
metastases, such as those from breast and prostate carcino-
mas, metastases may show low signal intensity on both T1-
and T2-weighted images because relatively less tumor is
present between the sclerotic trabeculae (which themselves
lack MR signal).
A rim of high signal surrounding a lesion (“halo sign”) or
diffuse signal hyperintensity of a lesion on T2-weighted
images have been reported as useful indicators in the
diagnosis of metastasis (sensitivity 75%; specificity 99.5%;
Fig. 3) [14]. This halo sign can potentially be useful in
Fig. 3 Halo sign in thyroid metastasis. a Coronal T1-weighted SE
MR image shows well-defined lesion of homogeneous low signal
intensity (arrows) in humeral shaft. b Coronal fat-suppressed T2-
weighted MR image demonstrates extensive, poorly defined high
signal surrounding lesion (arrows), consistent with edema
Fig. 2 Multifocal Hodgkin dis-
ease, with false-negative blind
marrow biopsy from the poste-
rior ilium. Axial a, b T1-
weighted and c, d corresponding
fat-suppressed T2-weighted SE
MR images show focal tumor
deposits in marrow of the right
iliac wing and left acetabulum
(long arrows). Note linear biop-
sy tract (short arrows) within
normal-appearing marrow of the
right posterior ilium; this biopsy
yielded a false-negative
marrow assessment
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evaluating small blastic metastases that might otherwise be
mistaken for bone islands (Fig. 4). In contrast, the bull’s-
eye sign, when present, has been shown to be a useful tool
in determining that a region of altered marrow signal is not
due to metastasis, with a specificity of 99.5% [14]. The sign
consists of one or more foci of high signal (due to fat)
present in marrow within a region of low signal intensity on
T1-weighted images.
Some tumors, such as small cell carcinoma, grow
between trabeculae within marrow without causing gross
trabecular or cortical destruction; similar growth may occur
in the earliest stages of tumor extension within marrow.
MRI is superior to radiographs and bone scan in detecting
such intertrabecular tumor deposits (Fig. 5); its sensitivity
(94.6%) is much higher than that of radiography (5.8%) or
bone scan (3.3%) [15]. In a study by Taoka et al. [16] for
detection of spinal metastases using MRI, corresponding
bone scans were positive in 71% of transcortical metasta-
ses, only 34% of subcortical metastases, and 0% of totally
intramedullary metastases. MRI clearly shows more metas-
tases than bone scans do, as many metastases do not have
cortical involvement.
Of note, one subtype of soft tissue sarcoma, myxoid
liposarcoma, is well known to produce asymptomatic
marrow metastases that are not evident on radiographs or
bone scan [17]. Such tumor deposits in marrow are readily
demonstrated on MRI (Fig. 6).
Post-treatment changes
During and after treatment for tumors in marrow, the
affected marrow undergoes substantial changes in its
chemical and cellular composition [18–20]. Because MRI
is sensitive and noninvasive in detecting changes in the
composition of marrow, MRI findings have been exten-
sively investigated to assess for early and late treatment-
related changes and for the presence of residual tumor.
Fig. 4 Halo sign in tiny metasta-
sis from prostate cancer. a Axial
T1-weighted SE MR image
shows tiny, ill-defined lesion with
low signal intensity (arrow) in the
right ischium. b Axial fat-sup-
pressed T2-weighted MR image
shows low signal intensity within
the lesion (long arrow), and
peripheral rim with high signal
intensity (“halo sign”; short
arrows). c Axial contrast-en-
hanced fat-suppressed T1-
weighted MR image reveals
mild enhancement of the rim
(halo) around the lesion
(arrows). d Lesion is sclerotic on
CT (arrow), and could have been
misdiagnosed as a bone island
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Changes in marrow signal due to radiation therapy
On both MRI and histopathologic evaluation, acute and
chronic changes induced by radiation treatment (RT) have
been well described [21–24]. In the acute phase, cellular
depletion, marrow edema, vascular congestion, and hemor-
rhage ensue during the first hours and days.Within 1–2weeks,
the observed increase in MR signal intensity in T2-weighted
and STIR images is thought to represent a reduction in
cellularity and an increase in fat and marrow edema [22, 24].
An increase in MR signal on STIR images can be observed
as early as 8 days after initiation of RT [22].
In the chronic phase of post-RT change, a high T1-
weighted MR signal of irradiated marrow compatible with
yellow marrow has been observed 3–7 weeks after the
initiation of RT (Fig. 7) [22]. In the spine, a band pattern of
peripheral, intermediate T1 signal intensity has also been
noted, and is thought to represent red marrow surrounding a
central fatty deposit [24].
The temporal evolution of MR signal changes in an
individual patient depends upon several factors. In a study
of 48 patients who underwent RT, Sacks et al. [19] reported
that the two most important factors affecting the ability of
marrow to regenerate are patient age and radiation dose.
They found that younger patients had superior marrow
recovery, with full marrow regeneration occurring in
patients under 18 years of age, independent of radiation
dose. Also, the capacity to regenerate marrow treated with a
dose greater than 40 Gy was less than in marrow treated
with a lower dose. Most regeneration occurred within
12 months of RT [19].
Although lesser and smaller, changes in MR signal are also
observed in bone marrow located outside the radiation portal
of the spine; the etiology of such changes remains unclear [22,
25]. Contrast enhancement of marrow both inside and
outside the radiation portal decreases significantly with time;
it has been speculated that this decrease in enhancement
represents reductions in cellularity and vascularity, and an
increase in fatty marrow in response to RT [25].
Radiation treatment-induced complications in the mar-
row include osteonecrosis, AVN, fractures, and radiation-
induced neoplasm, and depend on factors such as
radiation dose, patient age, size of the radiation field,
and beam energy [26]. Cell death and devascularization of
bone occur after doses exceeding 5,000 cGy [26]; these
events impair hematopoietic regeneration and normal bone
formation. Osteonecrosis/AVN is localized within the
radiation portal and usually is diagnosed years after RT;
typical locations include the mandible, clavicle, humeral
head, rib, and femur. On MRI, the presence of high signal
intensity inside a low-intensity peripheral rim on T2-
weighted images (the “double line” sign) is specific for the
diagnosis of AVN [27].
Fractures of irradiated bones, such as sacral insufficiency
fractures or collapsed vertebrae, can occur within a few
months of RT and may present diagnostic challenges by
mimicking osseous metastases. Correct diagnosis is imper-
ative to avoid unnecessary biopsies and to guide proper
clinical management. Particularly in patients with osteopo-
rosis (such as postmenopausal women), fracture risk after
RT is substantially increased. Abe et al. [28] reported a 34%
prevalence of sacral insufficiency fractures in a retrospec-
tive study of 80 patients who underwent bone scanning; of
note, all insufficiency fractures were identified in postmen-
opausal women. Multiple fractures may develop within
24 months [29]. The incidence of RT-induced sacral
insufficiency fractures seen on MRI is 20–80% [29, 30].
The fracture lines usually parallel the sacroiliac joints and
show ill-defined margins in all sequences. MRI may
demonstrate the fractures earlier than CT by revealing
surrounding edema, before fracture lines become visible on
CT (Fig. 8).
Radiation treatment-induced bone tumors can be benign
or malignant. The prevalence of (benign) osteochondroma
after RT in patients with unfused physes has been reported
to be 12% at 8 years—a prevalence incidence higher than in
Fig. 5 Extent of marrow involvement in osteosarcoma. a, b
Anteroposterior radiographs show a classic osteosarcoma in the distal
femur; the exact proximal extent of the tumor is unclear. c Coronal
T1-weighted SE MR image readily shows the proximal extent of
abnormal marrow (arrow), which extends into the proximal diaphysis
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spontaneous osteochondroma (1%) [31]. An RT-induced
sarcoma of bone is rather rare, constituting less than 1.5%
of all bone sarcomas [32]. By definition, the sarcoma must
be histologically distinct from the original treated lesion,
and occur within the irradiated field, typically after a long
latent period [33]. Although the lowest dose required to
induce a sarcoma is not established, studies have suggested
that there is an association between the radiation dose and
subsequent risk of sarcoma. In a study of 16 patients after
RT for Ewing sarcoma, Kuttesch et al. [34] reported that no
secondary sarcoma was observed if the radiation dose was
less than 48 Gy; excess risk of a secondary sarcoma was
associated with radiation doses greater than 60 Gy, con-
firming the findings of previous studies. High-grade
osteosarcoma, fibrosarcoma and malignant fibrous histio-
cytoma are the most common histologic types of radiation-
induced sarcomas. The mean latency period ranges from 14
to 17 years (although some have occurred as soon as 3 years
after RT), and the tumors are usually radioresistant [32, 35].
RT-induced sarcomas were initially considered to have a
grave prognosis compared with primary bone sarcoma, but
subsequent studies have shown that aggressive treatment
with chemotherapy and surgical resection improves the
prognosis of RT-induced sarcomas, resulting in more than a
60% 5-year survival rate—approaching that of a primary
bone sarcoma (50–80% 5-year survival rate) [33, 35].
Changes in marrow signal due to chemotherapy
Upon initiation of chemotherapy, marrow signal becomes
hypointense on T1-weighted images and hyperintense in
fat-suppressed T2-weighted and STIR images, reflecting
marrow congestion [36]. About 3–4 weeks into chemother-
apy, reconversion from fatty marrow to hematopoietic
marrow can occur, and is readily recognized as it usually
occurs in the reverse sequence of marrow conversion, both
bilaterally and symmetrically. After chemotherapy, depletion
Fig. 6 Occult marrow metasta-
sis myxoid liposarcoma. a
Coronal T1-weighted SE MR
image shows large lesion with
low signal intensity (arrow) in
the marrow of the right proximal
femur, representing metastasis
from a previously resected
myxoid liposarcoma of the soft
tissues of the right distal thigh.
Abnormal signal in the adjacent
soft tissues of the lateral hip
(asterisk) reflects biopsy
changes. bMarrow metastasis in
the right proximal femur is
radiographically occult, and was
not visible on the bone scan (not
shown). (Case courtesy of
Cristina Antonescu, MD, Me-
morial Sloan-Kettering Cancer
Center, New York, NY, USA)
Fig. 7 Post-radiation marrow
changes in the thoracic spine.
Sagittal T1-weighted SE MR
image shows diffuse fatty mar-
row throughout the portion of
the thoracic spine that had been
included within the radiation
therapy port; the most cephalad
and caudad vertebrae included
in the port are indicated by
asterisks. Therapy was directed
at spinal metastases (the largest
located within the T8
vertebral body)
1022 Skeletal Radiol (2007) 36:1017–1027
of hematopoietic marrow may result in a predominantly fatty
marrow [18, 36].
Several drugs used in oncology patients can cause
various side effects in immature and mature skeletons,
some of which can be misdiagnosed as tumors on MRI.
Osteopenia, fractures, osteonecrosis, and AVN (Fig. 9) are
well-known complications of prolonged administration of
steroids in patients of all ages. In children, methotrexate can
cause osteopenia, severe bone pain and metaphyseal
insufficiency fracture (described as methotrexate osteopa-
thy) [37]. In breast cancer treatment, both hormonal therapy
with aromatase inhibitors in postmenopausal women and
chemotherapy-induced ovarian failure in premenopausal
women can cause significant loss of bone mass, increasing
the risk of fractures [38].
Bisphosphonates (BP) are osteoclast inhibitors that can
be used for the treatment of bone loss and bone pain in
metastatic disease and multiple myeloma. Cases of osteo-
necrosis of the jaw in patients treated with BP have been
recently and increasingly reported, strongly suggesting a
causal link [39]. Osteonecrosis of the jaw is usually painful
and preceded by a dental procedure in 60% of cases. Over-
suppression of bone turnover and antiangiogenic effects of
BP are considered to be contributing factors [39, 40].
The effects of granulocyte-colony stimulating factor (G-
CSF) in bone marrow are often encountered on MRI, as G-
CSF is increasingly used in conjunction with chemotherapy.
G-CSF is an agent used to promote hematopoietic activity
(specifically, stimulation of the granulocyte cell line) in
order to decrease the incidence of chemotherapy-induced
neutropenia. Multiple areas of red marrow develop in
conjunction with increasing neutrophil counts. However,
there is no apparent relationship between the number of
treatment courses of G-CSF and the extent of red marrow
reconversion (Fig. 10) [41]. The signal characteristics of the
changes in marrow are similar to those of red marrow in
both pediatric and adult patients [42, 43]. Although this
drug-induced red marrow can simulate marrow disease on
MRI, combined knowledge of the effects of G-CSF on
marrow and the clinical status of individual patients can
help to avoid misdiagnosing this treatment-related effect as
an interval development of metastases [44]. For example, it
would be highly unusual for multiple bone metastases to
develop in a patient whose primary tumor was either
unchanged or decreasing in size during chemotherapy; in
such a case, it would be appropriate to report the new
findings in the marrow as being consistent with the effects
of marrow-stimulating therapy.
Fig. 8 Sacral insufficiency fracture in postmenopausal woman treated
with radiation 2 years earlier for cervical cancer. a Bone scan (anterior
view) shows intense focal uptake (arrow) in the right sacrum, initially
interpreted as metastasis. b Axial T1-weighted SE MR image shows
abnormal marrow signal in the right sacral ala (arrow), which could be
consistent with metastasis. c Axial contrast-enhanced fat-suppressed
T1-weighted gradient echo MR image, however, shows linear low
signal (arrows) within corresponding region, diagnostic of sacral
insufficiency fracture. No fracture was visible on initial CT (not
shown). d CT obtained 5 months later clearly demonstrates (now)
bilateral sacral insufficiency fractures (arrows)
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Complementary MR techniques under development
Although MRI is effective in diagnosing and monitoring
malignant marrow diseases, it lacks specificity in distin-
guishing viable tumor from treatment-related changes
(Fig. 11) [45, 46]. Hanna et al. [45] correlated MRI
findings in a variety of disseminated marrow diseases with
marrow biopsies at 21 sites and found that MRI was
nondiscriminatory in differentiating post-treatment
changes from malignant disease in all MR sequences
obtained. Seven lesions were found to contain viable
tumor at biopsy; the majority of T1-weighted, T2-
weighted, and STIR sequences showed abnormal signal
in these lesions, and all post-contrast sequences showed
lesional enhancement. However, among 14 lesions that did
not contain viable tumor at biopsy, abnormal signal was
present in the lesions on the majority of T1-weighted, T2-
weighted, and STIR sequences, and enhancement was
present in more than half of the lesions on post-contrast
sequences. These findings underscore the lack of specific-
ity of signal changes on MRI for distinguishing viable
tumor and post-treatment changes.
In order to increase the specificity and accuracy of MRI
in the clinical setting, different MR techniques have been
investigated, mainly focusing on the quantitative assess-
ment of a variety of parameters. Techniques that have been
evaluated include quantitative T1 relaxation time measure-
ment, diffusion-weighted echo-planar imaging (EPI),
chemical shift imaging, and dynamic contrast enhancement
[47–53]. Although still in a relatively early stage of
development, these techniques have shown the potential
to complement conventional MRI. For example, in quantita-
tive analyses of T1 relaxation time in leukemia by Vande Berg
et al. [49], a decrease in T1 values in acute lymphocytic
leukemia showed a correlation with therapy response (a
mean 50% decrease in T1 values in patients with a response,
versus a mean 18.7% decrease in patients without a
response), whereas T1 values in acute myeloid leukemia
did not. However, in a study of quantitative MRI using T1
relaxation times, Lecouvet et al. [51] reported that MRI
failed to detect leukemic marrow infiltration in 41% of
patients with chronic lymphocytic leukemia.
In a study of lymphoma involving iliac bone marrow by
Yasumoto et al. [47], the sensitivity and specificity of
diffusion-weighted EPI imaging (77% and 97%, respec-
tively) were statistically similar to those of fast SE STIR
imaging (85% and 97% respectively). T1-weighted imaging
had higher sensitivity (92%) but lower specificity (77%)
than diffusion-weighted EPI [47]. The EPI technique is
limited by poor spatial resolution and by susceptibility and
chemical shift effects [52]. Quantitative chemical-shift
imaging enables the quantitative assessment of fat content
in bone marrow, thus allowing for noninvasive monitoring
of temporal changes in marrow composition [48, 53]. In a
study of 11 patients with acute leukemia by Gerard et al.
[48], sequential increases in fat fraction were correlated
with the estimated fat fraction on biopsy, which reflects
clinical remission; however, the baseline fat fraction and the
increases in fat fraction were variable across individuals.
For more than a decade, a potential role for dynamic
contrast-enhanced MRI has been explored in the assess-
ment of the percentage of necrosis present within a bone
tumor after treatment. This research is motivated by the
finding that the percentage of necrosis following neo-
Fig. 9 Marrow infarcts after
chemotherapy for acute lym-
phoblastic leukemia. a Sagittal
T1-weighted SE MR image
shows typical serpiginous rims
with low signal intensity sur-
rounding regions of fatty mar-
row in distal femur and
proximal tibia. b Sagittal fat-
suppressed T2-weighted MR
image shows a double-line sign
(arrow), consisting of an inner
band of high signal intensity and
an outer band of dark signal
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adjuvant chemotherapy portends patient prognosis in
osteogenic sarcoma [54, 55]. In a study of 50 cases of
osteogenic sarcoma and Ewing sarcoma by Dyke et al. [50],
quantitative estimates of tumor necrosis obtained using
dynamic contrast-enhanced MRI were shown to be strongly
correlated with the percentage of necrosis determined by
pathologic evaluation (using the Huvos grading system),
particularly in making the clinically relevant distinction
between those tumors that are less or more than 90%
necrotic. These findings suggest that dynamic MRI could
be valuable for noninvasively assessing treatment response
during neoadjuvant therapy, potentially allowing a change
to be made in that therapy for those patients whose
response is poor. Currently, the software used for data
analysis is developed at each institution that performs
necrosis studies; until some such proprietary software is
made commercially available, the utility of this technique
will be limited.
Recent advances in MR technology have made whole-
body MRI (WBMRI) possible in a single session. For
example, the introduction of a rolling-table platform
with integrated surface coils has eliminated previously
time-consuming changes in position of both patient and
coils, and sequences such as breath-hold gradient echo
and whole-body turbo STIR have substantially shortened
scan time—in some cases to a total scan time of less
than 15 min—while also providing good spatial resolu-
tion [56–58]. Given its high sensitivity in the detection of
Fig. 10 Marrow changes due to
G-CSF treatment after chemo-
therapy for osteogenic sarcoma
of proximal tibia. a Axial T1-
weighted SE MR image shows
several small, ill-defined foci of
slightly decreased signal inten-
sity (arrows) relative to fatty
marrow in ankle. b Axial fat-
suppressed T2-weighted MR
image shows corresponding
high signal intensity within the
foci (arrows). In this clinical
scenario, these MR findings are
compatible with islands of red
marrow developing due to treat-
ment with G-CSF, and should
not be mistaken for metastases
Fig. 11 Treatment effect versus
residual viable osteosarcoma in
proximal tibia after neoadjuvant
chemotherapy. Coronal a fat-
suppressed T2-weighted MR
image and b corresponding
gross pathology specimen show
extensive abnormality within the
marrow of the tibia. The amount
of residual viable tumor cannot
be assessed by visual inspection
of the MR image or gross
specimen. Histopathologic anal-
ysis using the Huvos method
determined that 40% of the
remaining lesion was necrotic,
indicating a poor (grade I) che-
motherapeutic response
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marrow lesions and excellent soft tissue contrast, WBMRI
is under investigation as a screening and staging modality
in oncology patients [56–61]. For example, WBMRI
appears to be both more sensitive and specific than
radiographic skeletal survey in assessing the extent of
multiple myeloma, which is critical in determining the
appropriate therapy [58, 59]. In a study of 51 patients,
Lauenstein et al. [60] compared WBMRI with CT,
conventional dedicated MRI, and bone scanning; they
found that WBMRI was more sensitive than those
conventional modalities in detection of hepatic and
osseous metastases. WBMRI and CT showed hepatic
metastases in 18 and 16 patients, respectively, whereas
WBMRI and bone scanning showed osseous metastases in
24 and 21 patients, respectively. They also found that
WBMRI and conventional modalities possess specific
advantages in different anatomic regions; for example,
WBMRI detected more osseous metastases in the spine
and pelvis, whereas bone scanning detected more metas-
tases in the skull and ribs. In a study of 129 patients,
Ghanem et al. [61] reported an 81% concordance between
WBMRI and bone scanning; among 24 discordant cases,
WBMRI detected osseous metastases in 15 cases that bone
scanning did not. Given the ongoing development of faster
and more efficient scanning techniques, the clinical utility of
WBMRI is likely to increase in the future.
Summary
Magnetic resonance imaging is an excellent noninvasive
modality for evaluating bone marrow and detecting
marrow lesions, as it provides information at the level
of cellular and chemical composition, in addition to
gross morphologic data. Knowledge of normal marrow
components and composition and their variation, as well
as of factors that alter MR signal intensity, is important
for optimal interpretation of MR images. The signal
intensity, morphology, and location of marrow findings
on MRI can be used to provide more accurate diagnoses,
to guide treatment, and to follow therapy-related changes.
Various MRI techniques are available to accentuate the
different chemical and cellular compositions of normal
marrow and marrow diseases. Although MRI is more
sensitive than specific in detecting marrow changes,
integrating all the clinical and radiologic data can result
in more useful interpretations. Recognition of post-
treatment effects, such as those associated with RT and
granulocyte-colony-stimulating factors, are important for
proper interpretation of MRI. In an attempt to overcome
the current limitations of MRI, several newer techniques
are under investigation that could increase the ability of
MRI to provide even more clinically relevant information
about marrow in oncology patients.
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